Appendix 4C - Quarterly - 31 March 2025
Filed with ASX · · 8 pages · English
Summary by 6ix AI
The report highlights the company's efforts to seek partnering opportunities for its products, implement cost reduction initiatives, and evaluate additional assets to diversify risk. As of the end of March, the company reported a cash balance and an expected R&D tax incentive refund, indicating its current financial position and future funding prospects. The report also outlines net cash outflows and the company's focus on business development and capital attraction amidst a challenging market environment.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Patrys
- Appendix 4D - Half Year Accounts - 31 December 2024
- Appendix 4C - Quarterly - 31 December 2024
- Appendix 4C - Quarterly - 30 September 2024
- PAT-DX1 clinical development update
- PAT-DX1 GMP specification testing update
Later from Patrys
- Suspension from Quotation
- Reinstatement to Official Quotation
- Successful Placement and Board Changes
- Deed of Release entered into with CEO
- Non-Renounceable Entitlement Offer
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys